Claim Missing Document
Check
Articles

Found 2 Documents
Search

What is the impact of Smoking on female fertility ? A Systematic Review Sharly Ayu Puspita; Dini Gustiarini
The International Journal of Medical Science and Health Research Vol. 14 No. 4 (2025): The International Journal of Medical Science and Health Research
Publisher : International Medical Journal Corp. Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70070/98yxwt81

Abstract

Introduction: Smoking is a significant public health concern with well-documented adverse effects on reproductive health. The toxins in cigarette smoke disrupt hormonal balances and physiological processes essential for conception and pregnancy. This systematic review aims to comprehensively assess the impact of tobacco use on female fertility, covering both natural conception and outcomes of assisted reproductive technologies (ART). Methods: This study adhered to the PRISMA 2020 guidelines. A systematic search was conducted across PubMed, Semantic Scholar, Springer, and Google Scholar using keywords related to female fertility, smoking, and reproductive outcomes. After screening 2,346 records and assessing 949 reports for eligibility, 22 studies were included in the final analysis. Results: The evidence shows that smoking significantly impairs natural fertility by increasing the time to pregnancy and raising the risk of an infertility diagnosis (OR 1.85) and ectopic pregnancy (OR 2.02). In ART, smokers experience significantly lower live birth rates (OR 0.52), reduced clinical pregnancy rates (OR 0.59), fewer retrieved oocytes, and a substantially higher miscarriage rate (OR 2.48) compared to non-smokers. Mechanistically, smoking is consistently associated with reduced Anti-Müllerian Hormone (AMH) levels, indicating diminished ovarian reserve. A clear dose-response relationship was identified, with heavier smoking linked to more severe outcomes. Discussion: The findings confirm that tobacco use is a potent reproductive toxin that compromises nearly every stage of the reproductive process, from oocyte quality to embryo implantation and development. The damage is not easily bypassed, even with advanced medical interventions. While the harm is evident, data on the reversibility of these effects after smoking cessation remains inconclusive, highlighting a critical knowledge gap. Conclusion: The evidence is overwhelming: smoking has a profoundly negative and multifaceted impact on female fertility. It is a significant barrier to achieving a successful pregnancy, regardless of the conception method. Therefore, smoking cessation counseling must be a primary and non-negotiable component of preconception and fertility care to preserve reproductive potential and improve pregnancy outcomes.
How do different treatment modalities impact long-term remission rates and fertility preservation in patients with gestational trophoblastic diseases? : A Systematic Review Sharly Ayu Puspita; Dini Gustiarini
The International Journal of Medical Science and Health Research Vol. 14 No. 5 (2025): The International Journal of Medical Science and Health Research
Publisher : International Medical Journal Corp. Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70070/nhahbb10

Abstract

Introduction: The management of Gestational Trophoblastic Disease (GTD) aims to achieve high long-term remission rates while preserving future fertility. Treatment protocols are stratified by risk to optimize outcomes and minimize toxicity. This systematic review synthesizes current evidence on how different treatment modalities impact remission and fertility in GTD patients. Methods: This systematic review adhered to PRISMA 2020 guidelines. Databases including PubMed, Semantic Scholar, Springer, and Google Scholar were searched using PICO-based keywords to identify relevant studies. After screening, 25 studies—including randomized controlled trials, cohort studies, and systematic reviews—were selected for data extraction and analysis on treatment protocols, remission rates, and fertility outcomes. Results: For low-risk Gestational Trophoblastic Neoplasia (GTN), single-agent chemotherapy (methotrexate or actinomycin D) achieves remission rates of 75-100%. For high-risk GTN, multi-agent regimens like EMA/CO result in remission rates between 71% and 97.7%. Immunotherapy with avelumab has shown approximately a 53% remission rate in chemo-resistant cases. Fertility preservation is a significant success, with subsequent pregnancy rates of 86.7-100% and live birth rates of 75.8-90% reported after chemotherapy. Surgical interventions such as routine second uterine curettage or hysterectomy did not demonstrate improved remission rates over chemotherapy alone. Discussion: The evidence strongly supports a risk-stratified treatment model that balances efficacy with toxicity. The choice between single agents like methotrexate and actinomycin D depends on their differing toxicity profiles. The emergence of immunotherapy has provided a crucial and effective option for patients with chemo-resistant disease, transforming the prognosis for this group. Conclusion: The treatment of GTD is highly effective, yielding excellent remission rates while safeguarding patient fertility. The standard of care relies on risk-stratified chemotherapy, with effective, evidence-based salvage therapies like immunotherapy available for resistant disease. These modern strategies ensure high cure rates and preserve quality of life, including future reproductive potential.